Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan

被引:21
|
作者
Hayashi, Kazuhiko
Katano, Yoshiaki
Takeda, Yasushi
Honda, Takashi
Ishigami, Masatoshi
Itoh, Akihiro
Hirooka, Yoshiki
Nakano, Isao
Yano, Motoyoshi
Goto, Hidemi
Yoshioka, Kentaro
Toyoda, Hidenori
Kumada, Takashi
机构
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Fujita Hlth Univ, Dept Internal Med, Div Liver & Biliary Dis, Toyoake, Aichi 47011, Japan
[3] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Japan
关键词
genotype; drug-resistance; phylogenetic analysis;
D O I
10.1002/jmv.20824
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis B virus (HBV) has been classified into eight genotypes and can be further divided into several subgenotypes that have different geographic distributions. Because of increased human migration, the prevalence of rare subgenotypes is increasing in Japanese patients with acute hepatitis B. Lamivudine-resistant strains of HBV have begun to emerge in association with chronic hepatitis B. The aim of this study was to investigate the distribution of HBV subgenotypes and lamivudine-resistant strains in patients in Japan with acute hepatitis B. One hundred twenty-three patients with acute hepatitis B and 123 with chronic hepatitis B were studied. HBV subgenotypes and lamivudine-resistance mutations were determined by direct sequencing of the preS and polymerase region, respectively. HBV subgenotypes Aa (n = 3), Ae (n = 23), Ba (n = 7), Bi (n = 3), Cs (n = 7), Ce (n = 76), D (n = 2), and H (n = 2) were detected in patients with acute hepatitis. In patients with chronic hepatitis, HBV subgenotypes Ae (n = 4), Ba (n = 1), Bj (n = 18), and Ce (n = 100) were found. Non-common Japanese subgenotypes, that is, non-Bj and non-Ce, were detected more frequently in patients with acute hepatitis (35.8%) than in patients with chronic hepatitis (4.1%) (Odds ratio, 0.076; 95% Cl, 0.029-0.200; P < 0.0001). Lamivudine-resistance mutations were detected in chronic hepatitis patients with breakthrough hepatitis but not in other patients. In conclusion, the prevalence of uncommon Japanese HBV subgenotypes is expected to increase, although larnivudine-resistant strains have not yet been found in patients with acute hepatitis B.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 50 条
  • [31] Hepatitis B virus mutations associated with lamivudine therapy in patients with chronic hepatitis B
    Asahina, Y
    Enomoto, N
    Nagayama, K
    Kurosaki, M
    Ogura, Y
    Izumi, N
    Marumo, F
    Sato, C
    HEPATOLOGY RESEARCH, 1999, 15 (02) : 145 - 156
  • [32] Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B
    Vassiliadis, T
    Nikolaidis, N
    Giouleme, O
    Tziomalos, K
    Grammatikos, N
    Patsiaoura, K
    Zezos, P
    Gkisakis, D
    Theodoropoulos, K
    Katsinelos, P
    Orfanou-Koumerkeridou, E
    Eugenidis, N
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (05) : 531 - 537
  • [33] Acute leukaemia in chronic hepatitis B patients with lamivudine therapy
    Chien, RN
    Yeh, CT
    Wang, PN
    Kuo, MC
    Hsieh, SY
    Shih, LY
    Liaw, YF
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (11) : 1088 - 1091
  • [34] Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection
    Shi, Ming
    Yang, Zhi-Jun
    Wang, Rong-Sheng
    Zhang, Hua
    Zhu, Ya-Fen
    Xu, Yong-Ping
    Lin, Qiu-Ye
    Jin, Li-Ji
    CLINICA CHIMICA ACTA, 2006, 373 (1-2) : 172 - 175
  • [35] Hepatitis B virus kinetics in acute hepatitis B - A comparison between lamivudine-treated and -untreated case
    Michitaka, K
    Kawai, K
    Matsubara, H
    Nakanishi, S
    Horiike, N
    Onji, M
    GASTROENTEROLOGY, 2001, 120 (05) : A385 - A385
  • [36] Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B
    Heo, Jeong
    Ahn, Sang Hoon
    Kweon, Young-Oh
    Kim, Byung-Ho
    Chan, Henry L. Y.
    Horban, Andrzej
    Wongcharatrawee, Suchat
    Llamoso, Cyril
    Lee, Kwan Sik
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (07) : 1485 - 1493
  • [37] Characterization of hepatitis B virus genotypes/subgenotypes in 1301 patients with chronic hepatitis B in North China
    Li Xiao-dong
    Wang Lin
    Liu Yan
    Xu Zhi-hui
    Dai Jiu-zeng
    Li Le
    Yao Zeng-tao
    Xin Shao-jie
    Zhao Jing-ming
    Xu Dong-ping
    CHINESE MEDICAL JOURNAL, 2011, 124 (24) : 4178 - 4183
  • [38] In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir
    Lada, O
    Benhamou, Y
    Cahour, A
    Katlama, C
    Poynard, T
    Thibault, V
    ANTIVIRAL THERAPY, 2004, 9 (03) : 353 - 363
  • [39] Screening of new antivirals for lamivudine-resistant hepatitis B virus.
    Ono-Nita, SK
    Kato, N
    Shiratori, Y
    Yoshida, H
    Kato, J
    Schinazi, RF
    Omata, M
    HEPATOLOGY, 1999, 30 (04) : 346A - 346A
  • [40] Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus
    Hosaka, T
    Suzuki, F
    Suzuki, Y
    Saitoh, S
    Kobayashi, M
    Someya, T
    Sezaki, H
    Akuta, N
    Tsubota, A
    Arase, Y
    Ikeda, K
    Kumada, H
    INTERVIROLOGY, 2004, 47 (06) : 362 - 369